Pre-made Vulinacimab benchmark antibody ( Whole mAb, anti-VEGFR2/KDR therapeutic antibody, Anti-CD309/FLK1/VEGFR Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-632

Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vulinacimab is a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-632-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody
INN Name Vulinacimab
TargetKDR
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesHenlix
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna